Welcome to our dedicated page for Regenerative Medical Technology Group news (Ticker: RMTG), a resource for investors and traders seeking the latest updates and insights on Regenerative Medical Technology Group stock.
Regenerative Medical Technologies Group, Inc. (RMTG) is a regenerative medicine company in the healthcare and biotechnology space, operating globally through its Global Stem Cells Group subsidiary. The RMTG news feed on Stock Titan highlights how the company combines stem cell and cellular therapies, biologic manufacturing, and physician education to build its presence in more than 30 countries.
News coverage for RMTG often focuses on international expansion and affiliate agreements, such as representation and partnership deals in Puerto Rico, northern Argentina and Paraguay, Brazil, and the Dominican Republic. These stories describe how local medical leaders are appointed to develop regional centers, training programs, and product distribution networks under the Global Stem Cells Group and ISSCA brands.
Another major theme in RMTG news is education and training events. Press releases detail ISSCA summits and in-country programs that bring together physicians and scientists for lectures, hands-on workshops, and certification in regenerative medicine protocols. These events generate revenue through registration fees, certification programs, exhibitor opportunities, and product sales, and they showcase the company’s CELLGENIC product line and manufacturing capabilities.
RMTG news also covers manufacturing developments and strategic partnerships, including the soft opening of an advanced cell therapy manufacturing facility in Cancún, Mexico, and a partnership with Bare Knuckle Fighting Championship to provide stem cell and regenerative treatments for fighters’ injuries. Financial updates, such as year-over-year sales growth and operating income, appear in earnings-related press releases.
Investors and healthcare professionals can use the RMTG news page to follow updates on geographic expansion, new affiliates, education initiatives, manufacturing milestones, and business performance as disclosed by the company.
Regenerative Medical Technologies Group (OTC:RMTG) launched the ISSCA AI™ Clinical Intelligence Platform, an AI system supporting regenerative and longevity medicine workflows. Built on a 30+ country physician network, millions of historical patient records, and the ISSCA Mobile App, it targets intake, protocols, predictive modeling, operations, and patient engagement, with plans to integrate education, biologics (CELLGENIC), and digital tools into a connected clinical ecosystem.
Global Stem Cells Group (OTC:RMTG) launched the physician-facing ISSCA Mobile App, created by its training arm ISSCA. The app digitizes a physician network spanning 30+ countries and centralizes regenerative and longevity medicine education, certifications, webinars, and collaboration, forming a scalable digital ecosystem and future base for ISSCA AI™.
Regenerative Medical Technologies Group (OTC:RMTG) reported strong Q1 2026 results, with revenue up 93% year over year to $2,639,353 and gross profit up 87% to $1,766,491. Operating income rose 70% to $229,783, and cash totaled about $1 million.
Training revenue (ISSCA) grew 433% to $772,005 and product supplies revenue (Cellgenic) increased 102% to $1,267,076, while patient procedures revenue was $600,273, roughly flat year over year. Growth is driven by the recurring-revenue Turnkey membership model and a clinic network in 30+ countries.
Regenerative Medical Technologies Group (OTCID:RMTG) announced that its Cellgenic biologics facility in Cancún has commenced full-scale xeno-free manufacturing and international distribution of six product lines to authorized professionals.
The facility adds a manufacturing revenue stream after Q1 2025 sales of $1.35M (67% YoY growth) and operational profits of $134,000, and the company launched an Authorized Distributor Program and a 2026 pipeline expansion including peptide formulations, secretome, and private-label manufacturing.
Regenerative Medical Technologies Group (OTCID:RMTG) announced CELLGENIC's expansion into the Dominican Republic via Global Stem Cells Group, adding product distribution and physician training through ISSCA.
Key elements include introduction of exosome products, MSC therapies, platelet-rich plasma kits, local leadership by Dra. Patria González and partners, and an ISSCA 2026 event planned for Q1 2026. The move complements RMTG's presence in Latin America and aims to create recurring revenue from product sales and certification programs. Recent operational momentum: Q1 2025 sales $1.35M (+67% growth) with $134,000 operational profit.
Regenerative Medical Technologies Group (OTCID:RMTG) announced expansion into Brazil via a strategic representation agreement with Julius Ladeira and a first major ISSCA conference in São Paulo on October 2-3, 2025. The agreement covers ISSCA education, CELLGENIC product distribution (exosomes, MSCs, PRP kits), and GSCG initiatives, aiming to serve Brazil's >600,000 physicians market where an estimated 30,000 already use regenerative approaches.
RMTG cited Q1 2025 sales of $1.35M (+67% growth) and operational profits of $134,000 as momentum supporting the expansion. The deal addresses Brazil's high import taxes by enabling local operations and revenue channels from training, product sales, and certifications.
Regenerative Medical Technologies Group (OTC:RMTG) announced that the ISSCA Regenerative Medicine Global Summit 2025 concluded Sept 12-13 at Secrets The Vine Cancún with full attendance from 30+ countries. The two-day program combined 14 keynote scientific presentations, five simultaneous hands-on certification workshops for 150 participants, exhibitor booths, and a soft opening tour of the new COFEPRIS-licensed CELLGENIC manufacturing laboratory. Revenue was generated via registration fees, certification programs, exhibitor booths, and product demonstrations while the event reinforced RMTG's integrated model of education, manufacturing, and distribution and highlighted recent geographic expansions.
Regenerative Medical Technologies Group (OTCID:RMTG) has announced a strategic partnership with Bare Knuckle Fighting Championship (BKFC) to become their official stem cell and regenerative medicine provider. The partnership aims to provide advanced treatments for fighters' sport-related injuries.
The collaboration addresses a critical need in combat sports, where fighters face high injury rates - 28-40 injuries per 100 fight participations, with facial lacerations (48%), hand injuries (13.5%), and nose injuries (10.4%) being most common. RMTG's stem cell therapies promise to cut healing time in half compared to traditional methods, while offering enhanced tissue regeneration and reduced inflammation.
This partnership with the world's fastest-growing combat sports league positions RMTG to showcase its regenerative medicine solutions to mainstream audiences and potentially expand into broader professional athletics markets.
Regenerative Medical Technologies Group (OTC:RMTG) announced the soft opening of its subsidiary Cellgenic's advanced cell therapy manufacturing facility in Cancun, Mexico during September 2025. The COFEPRIS-licensed facility will manufacture cell-based therapies including mesenchymal stem cells, exosomes, and NK cells.
The facility, set for full-scale operations by January 2026, will serve as both a Stem Cell Collection Center and Stem Cell Bank. The company reported Q1 2025 sales of $1.35M, showing 67% growth with operational profits of $134,000. The opening coincides with the 2025 ISSCA Regenerative Medicine Global Summit, expecting to attract over 200 physicians and scientists from 30+ countries.
Regenerative Medical Technologies Group (OTCID:RMTG) has announced the strategic appointment of Dr. José Luis Décima, former Minister of Health for Formosa province, as its representative for northern Argentina and Paraguay through its Global Stem Cells Group subsidiary. This expansion strengthens RMTG's presence in underserved Latin American markets.
The company reported strong financial performance with Q1 2025 sales of $1.35M, showing 67% growth and operational profits of $134,000. The new affiliate program, launching in Q3, is expected to generate up to $500,000 in upfront membership fees. RMTG's network currently spans over 30 countries, offering training, product sales, and certification programs.